Atezolizumab-induced Encephalitis in Metastatic Bladder Cancer: A Case Report and Review of the Literature

Clin Genitourin Cancer. 2017 Oct;15(5):e847-e849. doi: 10.1016/j.clgc.2017.03.001. Epub 2017 Mar 16.

Authors

Jeffrey J Levine¹, Robert A Somer², Hitomi Hosoya³, Christian Squillante²

Affiliations

¹ Department of Hematology and Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ. Electronic address: levine-jeffrey@cooperhealth.edu.
² Department of Hematology and Oncology, MD Anderson Cancer Center at Cooper University Hospital, Camden, NJ.
³ Department of Internal Medicine, Pennsylvania Hospital of the University of Pennsylvania, Philadelphia, PA.

PMID: 28372981
DOI: 10.1016/j.clgc.2017.03.001

No abstract available

Keywords: Altered mental status; Immune check point inhibitor; Immunotherapy; PD-L1 inhibitor; Urothelial cell carcinoma.

Publication types

Case Reports
Review

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Encephalitis / chemically induced*
Encephalitis / drug therapy
Female
Humans
Middle Aged
Steroids / therapeutic use
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Steroids
atezolizumab